# Actinic Keratosis

Manage actinic keratosis by identifying lesions that require biopsy to exclude squamous cell carcinoma, then selecting lesion- or field-directed treatment based on burden, location, recurrence, tolerability, and cosmetic priorities.

**Clinical question:** How should physicians distinguish actinic keratosis requiring biopsy from lesions suitable for lesion- or field-directed treatment?

Updated: 2026-09-15T23:12:03.587409+00:00

## What matters in practice
- Biopsy an AK-like lesion that is larger than 1 cm, bleeding, ulcerated, indurated, rapidly growing, or persistently erythematous; pain, marked hyperkeratosis, pigmentation, treatment failure, and atypical morphology also lower the threshold for histopathology. [17]
- Use lesion-directed therapy for limited discrete AKs; use field therapy when multiple visible and subclinical lesions occur within chronically photodamaged skin. [5][7][10][24]
- Cryotherapy, 5-fluorouracil, imiquimod, tirbanibulin, diclofenac, and photodynamic therapy are established treatment options; select among them according to lesion distribution, inflammatory tolerance, adherence feasibility, and cosmetic goals. [5][7][9][24]
- Dermoscopy can support clinical diagnosis and longitudinal assessment, but concerning or treatment-refractory lesions still require biopsy rather than repeated empiric AK treatment. [17][19][24]
- AKs are intraepidermal keratinocytic neoplasms with potential progression to cutaneous squamous cell carcinoma; one retrospective estimate suggested progression over a mean 24.6 months among lesions that transform. [12][18]

## Identify lesions that need biopsy before AK treatment

Do not destroy a lesion clinically concerning for invasive keratinocyte carcinoma without obtaining tissue.

Clinical diagnosis is usually sufficient for a typical rough, scaly lesion on chronically sun-exposed skin, but dermoscopy is useful when morphology is uncertain or when documenting response and recurrence. Dermoscopy improves diagnostic assessment but does not replace histopathology when invasive SCC, pigmented malignancy, or another mimic remains plausible. [17][19][24]

Perform biopsy before routine destructive or field treatment for a lesion larger than 1 cm, bleeding, ulcerated, indurated, rapidly enlarging, or prominently erythematous. These features raise concern for progression to SCC or an alternative diagnosis. Biopsy is also appropriate for intense pruritus or pain, marked hyperkeratosis, palpable thickening, pigmentation, unusual morphology, or failure to respond to usual AK treatment. [17]

Treat a persistent suspicious lip lesion as a separate high-risk problem: actinic cheilitis may clinically resemble AK, yet lesions presumed premalignant can prove to be SCC on histology. Biopsy is the diagnostic standard for a persistent suspicious lesion on the lip; SCC arising on the lip has higher metastatic potential than SCC at many other cutaneous sites. [23]
- Pigmented facial lesions require careful distinction from lentigo maligna, in addition to solar lentigo, seborrheic keratosis, and lichenoid keratosis; obtain histopathology when clinical and dermoscopic assessment does not establish a confident diagnosis. [17][22]
- If a lesion persists after a completed treatment course, reassess the original diagnosis and biopsy rather than automatically repeating field therapy. [17][24]

*Clinical findings that change management from empiric AK treatment to histopathologic evaluation. [17][23]*

| Finding | Clinical concern | Next action |
| --- | --- | --- |
| Diameter >1 cm, bleeding, ulceration, induration, rapid growth, or marked erythema | Invasive SCC or another keratinocytic neoplasm | Biopsy before destructive treatment. [17] |
| Pain, intense pruritus, marked hyperkeratosis, palpable thickening, or atypical morphology | Higher-risk AK or SCC mimic | Lower threshold for biopsy. [17] |
| Pigmented facial lesion with diagnostic uncertainty | Lentigo maligna or other pigmented lesion | Use dermoscopy; biopsy if uncertainty persists. [17][22] |
| Persistent suspicious lower-lip lesion | Actinic cheilitis versus lip SCC | Biopsy for histopathologic diagnosis. [23] |
| No response to usual AK treatment | Misdiagnosis, residual dysplasia, or SCC | Reassess and obtain biopsy when clinically persistent. [17][24] |

## Match treatment to lesion burden and field cancerization

The central treatment choice is whether to target individual lesions or the surrounding photodamaged field.

Choose lesion-directed treatment for a limited number of discrete lesions. Liquid-nitrogen cryotherapy is a standard destructive option; curettage with or without electrodesiccation is another destructive approach listed for AK management. Surgical excision is a lesion-directed option when tissue diagnosis or definitive removal is needed, particularly when SCC cannot be excluded clinically. [5][24]

Choose field-directed therapy for multiple AKs or recurrent lesions within a contiguous sun-damaged area because visible lesions coexist with subclinical disease in the cancerization field. Field options include topical 5-fluorouracil, imiquimod, tirbanibulin, diclofenac, and photodynamic therapy. [5][7][10][24]

Do not interpret short-term clearance comparisons as proof that one field treatment is universally best. In relapsing AK after diclofenac, a prospective randomized comparison of 5-fluorouracil 4%, tirbanibulin, and PDT found no statistically significant short-term differences in clearance or recurrence; the study was not powered to establish equivalence. Individualize selection around site, number of lesions, expected inflammation, treatment duration, access, and cosmetic preference. [7]
- Use photodynamic therapy when a field approach and cosmetic outcome are priorities; it has been associated with good cosmetic results and high patient satisfaction in comparative discussions. [6][24]
- Consider diclofenac when a milder inflammatory profile is especially important; field-treatment guidance characterizes it as an option when less inflammation is desired. [7]
- Chemical peels have been used off-label for multiple or clustered AKs; they should not substitute for biopsy of lesions with features concerning for SCC. [24]

*Practical treatment-scope selection for actinic keratosis. [5][7][24]*

| Clinical pattern | Preferred treatment scope | Reasonable modalities | Decision tradeoff |
| --- | --- | --- | --- |
| Few, discrete typical AKs | Lesion-directed | Cryotherapy; curettage with or without electrodesiccation. [5] | Efficient focal treatment but does not address subclinical disease outside treated lesions. [7][10] |
| Multiple AKs in a contiguous photodamaged area | Field-directed | 5-fluorouracil, imiquimod, tirbanibulin, diclofenac, or PDT. [5][7][24] | Treats visible and subclinical field disease but requires tolerance of local reaction or procedural logistics. [7][24] |
| AK-like lesion with SCC warning features | Diagnostic procedure first | Skin biopsy; excision when clinically indicated. [17][24] | Avoids losing histologic diagnosis through empiric destruction. [17] |
| Extensive facial field disease with cosmetic priority | Field-directed | Photodynamic therapy. [6][24] | Procedural treatment may offer favorable cosmetic outcomes and satisfaction. [6][24] |

## Use topical and photodynamic therapies with regimen-specific counseling

Counsel that erythema, crusting, and irritation are expected with several effective field treatments.

Topical 5-fluorouracil is a field-directed option for AK. In a split-face study of facial field cancerization, 5-fluorouracil was applied twice daily for 15 days; this is a study regimen rather than a universal regimen. Select topical therapy only when the patient can apply treatment to the defined field and return for reassessment of persistent lesions. [10][24]

Topical 5-fluorouracil plus calcipotriene is an off-label short-course field strategy. Reported courses are commonly 4 to 7 days, intended to augment a T-cell-mediated response against dysplastic keratinocytes while reducing treatment duration compared with traditional 5-fluorouracil monotherapy. Anticipate erythema, crusting, and localized irritation; assess residual focal lesions after reaction resolves. [24]

Imiquimod and tirbanibulin are additional field-directed topical options. Their principal operational advantage is avoidance of an in-office light procedure; their limitation is that successful treatment depends on adherence to the prescribed application schedule and recognition of local treatment reactions. Current AK guidance includes a focused update addressing tirbanibulin. [5][14][15][24]

Photodynamic therapy is a field procedure using a topical photosensitizer and light activation. Methyl aminolevulinate-PDT has been compared with liquid-nitrogen cryotherapy in a multicenter randomized study, and PDT is used for AKs with an established reputation for efficacy and cosmetic results. Consider PDT when a procedure-based field treatment is preferable to prolonged topical application. [6][10][24]
- Before starting topical, cryosurgical, PDT, or combination treatment, define the anatomic field and establish how treatment reaction, adherence, and residual lesions will be assessed. [14]
- At post-treatment review, biopsy any lesion that remains indurated, ulcerated, enlarging, painful, or otherwise discordant with expected AK response. [17][24]

*Field-directed options and selection variables for AK. [5][7][10][24]*

| Option | Use case | Documented regimen detail | Key limitation or counseling point |
| --- | --- | --- | --- |
| 5-fluorouracil | Topical field treatment for multiple AKs. [5][24] | A facial field-cancerization study used twice-daily application for 15 days. [10] | Requires adherence and reassessment of persistent lesions. [17][24] |
| 5-fluorouracil plus calcipotriene | Off-label short-course field therapy. [24] | Courses commonly reported as 4-7 days. [24] | Expect erythema, crusting, and localized irritation. [24] |
| Imiquimod | Topical field treatment. [5][24] | Specific dosing regimen not standardized here. | Local treatment reaction and adherence affect feasibility. [14][24] |
| Tirbanibulin | Topical field treatment. [5][7][24] | Specific dosing regimen not standardized here. | Guidance includes a focused update; use current product and guideline instructions. [15] |
| Diclofenac | Topical field treatment when less inflammation is desired. [5][7] | Specific dosing regimen not standardized here. | May be selected for a milder inflammatory profile. [7] |
| Photodynamic therapy | Procedure-based field therapy, especially when cosmetic result is important. [6][24] | Methyl aminolevulinate-PDT has been studied against cryotherapy. [6] | Requires photosensitizer-light procedure access and visit-based treatment. [6][10] |

## Monitor treated fields and reduce future AK burden

Follow-up should distinguish expected treatment reaction from residual or newly suspicious lesions.

At each follow-up, examine the treated field for persistent thick, tender, indurated, ulcerated, bleeding, or enlarging lesions and direct these lesions to biopsy. Dermoscopy can support serial assessment of clinical response and recurrence, particularly in patients with numerous lesions where routine biopsy of each site is impractical. [17][19]

Explain the reason to treat and surveil: AKs may progress to invasive SCC. A retrospective electronic-record study estimated that approximately 10% of AKs progress to SCC and that mean time to progression among transforming lesions was 24.6 months; this estimate should inform vigilance, not lesion-specific prediction. [12]

Prescribe ongoing UV protection as a core prevention strategy for patients with AK or ongoing risk. A contemporary clinician review also identifies oral nicotinamide as a preventive strategy that can reduce lesion formation and recurrence; determine use in the context of the patient's broader skin-cancer risk profile and concurrent care. [14][24]
- Reassess recurrent disease as field cancerization rather than repeatedly treating only the most visible lesions when multiple AKs recur in the same photodamaged area. [7][10]
- Use noninvasive imaging as an adjunct for diagnosis or monitoring when available; do not allow reassuring imaging to override biopsy indications created by clinical evolution. [17][19]

*Post-treatment findings and next actions. [17][19][24]*

| Follow-up finding | Interpretation | Next action |
| --- | --- | --- |
| Expected localized erythema, crusting, or irritation during topical field therapy | Common treatment effect with 5-fluorouracil-calcipotriene therapy. [24] | Assess after the planned course; evaluate persistent focal lesions. [17][24] |
| Persistent or recurrent typical thin AKs across a photodamaged field | Ongoing field cancerization. [7][10] | Consider field-directed treatment rather than lesion-only management. [5][7][24] |
| Persistent induration, ulceration, bleeding, rapid growth, or lesion pain | Possible SCC or alternate diagnosis. [17] | Biopsy. [17] |
| Diagnostic uncertainty during surveillance | Clinical examination may be insufficient. [24] | Use dermoscopy as an adjunct; biopsy unresolved concern. [17][19][24] |

## References
1. Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/2763685
2. Core Outcome Set for Actinic Keratosis Clinical Trials - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jamadermatol/articlepdf/10.1001/jamadermatol.2019.4212
3. Human Papillomavirus Vaccination and Actinic Keratosis Burden — jamanetwork.com — https://jamanetwork.com/journals/jamadermatol/articlepdf/10.1001/jamadermatol.2025.0531
4. Evaluation of Long-term Clearance Rates of Interventions for Actinic ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/2782523
5. Actinic keratosis - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/616?c=suggested&q=Actinic+keratosis
6. Actinic Keratosis: Photodynamic Therapy or Cryotherapy? | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/actinic-keratosis-photodynamic-therapy-cryotherapy-JD200209250000005
7. Randomized comparative study of 5-Fluorouracil 4%, tirbanibulin ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1572100026000268
8. Solar keratoses: Photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0738081X13000746
9. What is the best treatment for actinic keratosis? : Evidence-Based Practice — journals.lww.com — https://journals.lww.com/ebp/fulltext/2010/09000/what_is_the_best_treatment_for_actinic_keratosis_.12.aspx
10. Clinical and histopathological study of actinic keratosis treatment with photodynamic therapy VS 5-fluorouracil for face cancerization - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1572100022002538
11. Non-melanoma skin cancers: Photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0738081X13001703
12. The Kinetics of Skin Cancer: Progression of Actinic Keratosis to Squamous Cell Carcinoma - FUCHS - 2007 - Dermatologic Surgery - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1524-4725.2007.33224.x
13. Creating pathways to navigate patient care — www.aad.org — https://www.aad.org/member/publications/impact/2022-issue-3/creating-pathways-to-navigate-patient-care
14. We’ve got new AK guidelines with CME credit — www.aad.org — https://www.aad.org/member/publications/impact/2023-issue-3/new-ak-guidelines
15. Actinic keratosis - American Academy of Dermatology — www.aad.org — https://www.aad.org/member/clinical-quality/guidelines/actinic-keratosis
16. The value of the histopathologic examination in the diagnosis and management of the actinic keratosis - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/23303015
17. Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects☆☆☆ — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6939186
18. Actinic Keratosis - StatPearls - NCBI Bookshelf — ncbi.nlm.nih.gov — https://ncbi.nlm.nih.gov/books/NBK557401
19. Digitally Enhanced Methods for the Diagnosis and Monitoring of Treatment Responses in Actinic Keratoses: A New Avenue in Personalized Skin Care — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10854727
20. Artificial Intelligence-Assisted Dermatologic Screening: Epidemiology and Clinical Features of Basal Cell Carcinoma, Squamous Cell Carcinoma, Seborrheic Keratosis and Actinic Keratosis — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12650624
21. Clinical and Dermoscopic Diagnosis of Actinic Keratosis — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11566822
22. Lentigo Maligna Melanoma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK482163
23. Actinic Cheilitis - StatPearls - NCBI Bookshelf — ncbi.nlm.nih.gov — https://ncbi.nlm.nih.gov/books/NBK551553
24. Actinic keratosis: A clinician's guide to diagnosis and treatment — www.ccjm.org — https://www.ccjm.org/content/93/9/541

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.